Dr. reddy's laboratories announces entry into definitive agreement with biodelivery sciences international, inc., to sell its u.s. and canada territory rights for elyxyb (celecoxib oral solution) 25 mg/ml

Hyderabad, india & princeton, n.j.--(business wire)--dr. reddy's laboratories limited (bse: 500124, nse: drreddy, nyse: rdy, nseifsc: drreddy, hereafter known as “dr. reddy's”), announced today that it has entered into a definitive asset purchase agreement, pursuant to which dr. reddy's will sell its u.s. and canada territory rights for elyxyb (celecoxib oral solution) 25 mg/ml, to biodelivery sciences international, inc. (bdsi). under the terms of agreement, dr.reddy's will receive u.s.$6 mill
RDY Ratings Summary
RDY Quant Ranking